Announcements

Positive Scientific Advice Meetings in Europe MoxDuo®IR 
26 July 2010

Appendix 4C Quarterly Report 
30 June 2010

Webcast Link: QRxPharma Presentation at Noble Financial's Equity Conference
11AM EDT, 7 June 2010
1 June 2010

ASX Spotlight: John Holaday, Managing Director and CEO, QRxPharma
24 May 2010

QRxPharma Successfully Completes Comparative Phase 1 Proof-of- Concept Study for MoxDuo®CR Tablet Formulation
10 May 2010

QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo®IR in Patients with Post-Surgical Pain
4 May 2010

Third  Quarter Operating Update
27 April 2010

QRxPharma Successfully Completes Pivotal Phase 3 Combination Rule Study for MoxDuo®IR in Patients with Post-Surgical Pain  
14 April 2010

QRxPharma Files IND for MoxDuo®CR; Initiates Phase 1 Trial of Controlled-Release Dual-Opioid™ Formulation for Use in Chronic Pain 
30 March 2010

QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo®IV 
23 February 2010

QRxPharma Limited ASX – Half-Year Report 31 December 2009  
17 February 2010

QRxPharma Initiates Second Pivotal Phase 3 Study of
MoxDuo™ IR Dual-Opioid™ for NDA Submission 
10 February 2010

Second Quarter Operating Update 
27 January 2010

Change of Director's Interest Notice - Gary Pace 
23 December 2009

Change of Director's Interest Notice - John Holaday 
23 December 2009

Change of Director's Interest Notice - Michael Quinn 
23 December 2009

Change of Director's Interest Notice - Peter Farrell 
23 December 2009

Change of Director's Interest Notice - Peter Campbell 
23 December 2009

Appendix 3B - Rights Issue 
23 December 2009

Change in substantial holding 
23 December 2009

Rights Issue - Notice of Despatch of Shareholder Statements 
21 December 2009

Notice of Subscriptions under Rights Issue 
18 December 2009

Appendix 3B Rights Issue
18 December 2009

Appendix 3Y Change of Director’s Interest Notice 
18 December 2009

Appendix 3Y Change of Director’s Interest Notice 
11 December 2009

Appendix 3Y Change of Director’s Interest Notice 
10 December 2009

Appendix 3Y Change of Director’s Interest Notice 
10 December 2009

Corporate Update and Rights Issue closing 15 December 2009 
10 December 2009

QRxPharma Initiates Pivotal Phase 3 Study of MoxDuo™IR For Moderate to Severe Acute Pain 
30 November 2009

Notice of Despatch of Rights Issue Documents to Shareholders
30 November 2009

Rights Issue - Notice to Ineligible Shareholders
30 November 2009

Rights Issue - Letter to U.S. Eligible Shareholders
30 November 2009

Appendix 3Y Change of Director’s Interest Notice 
23 November 2009

Appendix 3B New Issue Announcement
23 November 2009

Appendix 3B New Issue Announcement
19 November 2009

QRxPharma Limited Announces A $21.6 Million Fully Underwritten Capital Raising
16 November 2009

QRxPharma Renounceable Rights Issue Booklet
16 November 2009

Renounceable Rights Issue - Entitlement and Acceptance Form
16 November 2009

Appendix 3B - Placement and Rights Issue
16 November 2009

Notification Section 708AA(2)(f) Corporations Act 2001 (Cth)
16 November 2009

Renounceable Rights Issue - Letter to Option holders
16 November 2009

Renounceable Rights Issue - Letter to Shareholders
16 November 2009

Reinstate ment to Official Quotation
16 November 2009

Chairman's and Managing Directors' Addresses to Shareholders
16 November 2009

Results of 2009 Annual General Meeting
16 November 2009

QRxPharma Corporate Presentation
13 November 2009

Voluntary Suspension from Trading
13 November 2009

Australian Securities Exchange Trading Halt
11 November 2009

First Quarter Operating Update 
26 October 2009

QRxPharma Announces Completion of Strategic Alliance Deal with Liaoning Nuokang Medicines Co Ltd for the Development of Venomics Assets
20 October 2009

QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo™CR 
12 October 2009

2009 Annual General Meeting
9 October 2009

Annual Report 2009
28 September 2009

QRxPharma Announces Strategic Alliance with Liaoning Nuokang Medicines Co Ltd for the Development of Venomics Assets
24 September 2009

M oxDuo™ IR Demonstrates Fewer Side Effects than Percocet®
25 August 2009

Appendix 4E – Preliminary Financial Report FY 2009
21 August 2009

Fourth Quarter Operating Update
28 July 2009

Third  Quarter Operating Update
27 April 2009

QRxPharma Successfully Completes Comparative Study for Dual-Opioid™ Pain Therapy 
20 April 2009

QRxPharma Limited ASX Half-Year Report – 31 December 2008
23 February 2009

QRxPharma Initiates Second Comparative Study for MoxDuo™ IR DualOpioid™ Pain Therapy
19 February 2009

Secon d Quarter Operating Update
28 January 2009

QRxPharma Initiates Comparative Study for MoxDuoIR™ Dual-Opioid™ Pain Therapy
16 December 2008

Notice of Change of Interests of Initial Substantial Shareholder
10 December 2008

Notice of Initial Substantial Shareholder
9 December 2008

2008 Annual General Meeting – Chairman and Managing Director
Addresses
4 November 2008

Results of 2008 Annual General Meeting
4 November 2008

Notice of Annual General Meeting
26 September 2008

Annual Report 2008
26 September 2008

QRxPharma On Track with Successful Completion During the Year of Initial Phase 3 Trials for its Lead Dual-Opioid® Q8003IR
21 August 2008

Fourth Quarter Operating Update
21 August 2008

Change of Director’s Interest Notice
12 August 2008

Appendix 4C: Quarterly Report for Entities Admitted on the Basis of Commitments
30 July 2008

Change of Director’s Interest Notice
3 July 2008

QRxPha rma Begins Trading on the International OTCQX 
1 July 2008

FY0 8 Appendix 4E — ASX Preliminary Final Report
30 June 2008

Change of Director's Interest Notice 
1 July 2008

Change of Director's Interest Notice 
30 June 2008

Change of Director's Interest Notice 
27 June 2008

Corporate Presentation 
June 2008

QRxPharma Releases Additional Phase 3 Data for Q8003IR ‘Dual Opioid’ Pain Therapy 
22 May 2008

Release of Shares from Restriction and Escrow 
19 May 2008

QR xPharma Releases Successful Phase 3 Study Results for 'Dual Opioid' Pain Therapy 
5 May 2008

Third Quarter Operating Update
28 April 2008

QRxPharma Limited ASX – Half-Year Report 31 December
2007
26 February 2008

Resignation of Company Secretary
15 February 2008

Second Quarter Operating Update
29 January 2008

QRxPharma Initiates Second Phase III Clinical Trial for its ‘Dual Opioid’ Pain Therapy 
13 December 2007

Change of Registered Office and Principal Administrative Office 
30 November 2007

Q RxPharma Enrolls First Patients in Phase III Clinical Trial Program for its ‘Dual Opioid’ Pain Therapy 
26 November 2007

Result of 2007 Annual General Meeting
2 November 2007

2007 Annual General Meeting - Chairman & Managing Director Addresses
2 November 2007

First Quarter Operating Update 
22 October 2007

Inve stor Update 
22 October 2007

Annual report 2007 
27 September 2007

Notice of Annual General Meeting 
27 September 2007

FY07 Results Corporate Presentation
Preliminary Final Report 
15 August 2007

FY07 Appendix 4E - Preliminary Final Report 
15 August 2007

ASX/Media Release - Preliminary Final Report 
15 August 2007

Appendix 4C Quarterly Report 
27 July 2007